A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Mechanism of Action
BG-68501 is a CDK2 Inhibitor
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad) alone and in combination with Fulvestrant
- How much of the study drug is absorbed into the blood and how fast it is removed
- How the study drug is acting on your body
Location
Similar Trials
Yes
No
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.